Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 5/20 | 0.64 |
| ▸ | CA1 | P00915 | 4/20 | 0.64 |
| ▸ | LMNA | P02545 | 3/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | THRB | P10828 | 1/20 | 0.64 |
| ▸ | APEX1 | P27695 | 1/20 | 0.64 |
| ▸ | HTR2B | P41595 | 1/20 | 0.64 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.64 |
| ▸ | CA12 | O43570 | 5/20 | 0.49 |
| ▸ | CA9 | Q16790 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | CA6 | P23280 | 1/20 | 0.31 |
| ▸ | CA5A | P35218 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14340040 | 0.81 | CA2 (0.61) | CA2CA1LMNACYP2C9SMN1; SMN2 | |
| SCHEMBL8429639 | 0.80 | CA2 (0.60) | CA2CA1LMNACYP2C9SMN1; SMN2 | |
| Hydrochlorothiazide SCHEMBL156490 | 0.78 | LMNA (1.00) | CA2CA1LMNACYP2C9SMN1; SMN2 | |
| Hydrochlorothiazide SCHEMBL9349 | 0.78 | LMNA (1.00) | CA2CA1LMNACYP2C9SMN1; SMN2 | |
| Hydrochlorothiazide SCHEMBL10778059 | 0.77 | LMNA (0.97) | CA2CA1LMNACYP2C9SMN1; SMN2 | |
| Hydrochlorothiazide SCHEMBL27630714 | 0.77 | LMNA (0.97) | CA2CA1LMNACYP2C9SMN1; SMN2 | |
| Hydrochlorothiazide SCHEMBL27674482 | 0.77 | LMNA (0.97) | CA2CA1LMNACYP2C9SMN1; SMN2 | |
| Hydrochlorothiazide SCHEMBL9508286 | 0.77 | LMNA (0.97) | CA2CA1LMNACYP2C9SMN1; SMN2 | |
| Hydrochlorothiazide SCHEMBL10408471 | 0.77 | LMNA (0.97) | CA2CA1LMNACYP2C9SMN1; SMN2 | |
| Hydrochlorothiazide SCHEMBL1333333 | 0.77 | LMNA (0.97) | CA2CA1LMNACYP2C9SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170209425-A1 | METHODS AND COMPOSITIONS FOR TREATING PATHOLOGIES ASSOCIATED WITH BDNF SIGNALING | UNIV CASE WESTERN RESERVE (US) | 2017-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170209425-A1 | METHODS AND COMPOSITIONS FOR TREATING PATHOLOGIES ASSOCIATED WITH BDNF SIGNALING | NTRK2, BDNF, NGF | CA2 2854/4885CA1 1283/4885LMNA 3206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.